TOP TEN perturbations for 38516_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38516_at
Selected probe(set): 205508_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38516_at (205508_at) across 6674 perturbations tested by GENEVESTIGATOR:
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):4.176076Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):4.046624Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.983511Number of Samples:5 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM1) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
Becker muscular dystrophy study 3 (biceps brachii) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.8212557Number of Samples:3 / 3
| Experimental | Becker muscular dystrophy study 3 (biceps brachii) |
| Biceps brachii biopsies obtained from patients with Becker muscular dystrophy (BMD). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.7247038Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.6295319Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM1) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.6100368Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.562231Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):3.4216423Number of Samples:2 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM1) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
basal cell carcinoma study 3 / normal epidermal keratinocytes
Relative Expression (log2-ratio):3.2628193Number of Samples:4 / 2
| Experimental | basal cell carcinoma study 3 |
| Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC). | |
| Control | normal epidermal keratinocytes |
| Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2. |
Organism: Homo sapiens
Gene: 38516_at
Selected probe(set): 204934_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38516_at (204934_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):4.136117Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)
Relative Expression (log2-ratio):3.8676538Number of Samples:3 / 5
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (psfmc) |
| CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.1964474Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.780693Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
prostate cancer study 1 (prim.) / benign prostate tissue
Relative Expression (log2-ratio):2.4820566Number of Samples:7 / 6
| Experimental | prostate cancer study 1 (prim.) |
| Primary prostate cancer samples. | |
| Control | benign prostate tissue |
| Benign prostate samples. |
prostate cancer study 8 (tissue) / adjacent prostate tissue
Relative Expression (log2-ratio):2.344263Number of Samples:5 / 5
| Experimental | prostate cancer study 8 (tissue) |
| Tumor tissue samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | adjacent prostate tissue |
| Histologically normal prostate tissue samples from patients with primary prostate cancer collected after radical prostatectomy. |
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):-2.299882Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |
2-(chloromethyl)pyridine hydrochloride study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-2.2956934Number of Samples:3 / 19
| Experimental | 2-(chloromethyl)pyridine hydrochloride study 1 (48h) |
| HepG2 cells exposed to 300μM 2-(chloromethyl)pyridine hydrochloride in DMSO solvent for 48 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 48 hours. |
stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)
Relative Expression (log2-ratio):-2.2932606Number of Samples:2 / 2
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | stem cell differentiation study 41 (hES-T3 EB) |
| Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype. |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):2.2784557Number of Samples:2 / 3
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |